World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
85
Citations
45146
World Ranking
14356
National Ranking
7259

Daniel P. Petrylak publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Daniel P. Petrylak sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 538 publications — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Daniel P. Petrylak D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Daniel P. Petrylak sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 85 D-Index — 29th percentile

29% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Daniel P. Petrylak is affiliated with Yale School of Medicine in the United States. Their research is primarily focused within the field of Medicine, with significant contributions in Surgery, Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, and Molecular Biology.

The scientist's main research topics cover several areas related to oncology and cancer treatment. These include:

  • Bladder and Urothelial Cancer Treatments
  • Cancer Immunotherapy and Biomarkers
  • Urinary and Genital Oncology Studies
  • Prostate Cancer Treatment and Research
  • Radiopharmaceutical Chemistry and Applications
  • Esophageal Cancer Research and Treatment
  • Peptidase Inhibition and Analysis

Research publications by Daniel P. Petrylak have appeared in several notable journals. The most frequent venues for publication are:

  • Journal of Clinical Oncology (100 publications)
  • Annals of Oncology (25 publications)
  • Clinical Cancer Research (9 publications)
  • European Urology (9 publications)
  • The Journal of Urology (8 publications)

Recent significant papers include the following:

  • "Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma," 2020, New England Journal of Medicine
  • "Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma," 2021, New England Journal of Medicine
  • "TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors," 2021, Journal of Clinical Oncology
  • "Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial," 2020, The Lancet Oncology
  • "Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial," 2021, The Lancet Oncology

Daniel P. Petrylak has collaborated extensively with several researchers. Frequent co-authors include:

  • Yohann Loriot (57 co-authored works)
  • Jonathan E. Rosenberg (53 co-authored works)
  • Petros Grivas (47 co-authored works)
  • Cora N. Sternberg (43 co-authored works)
  • Thomas Powles (40 co-authored works)

Best Publications

  • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    Jonathan E Rosenberg;Jean Hoffman-Censits;Tom Powles;Michiel S van der Heijden

  • Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

    Daniel P. Petrylak;Catherine M. Tangen;Maha H.A. Hussain;Primo N. Lara

  • MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    Thomas Powles;Joseph Paul Eder;Gregg D. Fine;Fadi S. Braiteh

  • Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

    Arjun V. Balar;Matthew D. Galsky;Jonathan E. Rosenberg;Thomas Powles

  • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

    Howard I. Scher;Susan Halabi;Ian Tannock;Michael Morris

  • Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

    Glenn J. Bubley;Michael Carducci;William Dahut;Nancy Dawson

  • Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

    Thomas Powles;Se Hoon Park;Eric Voog;Claudia Caserta

  • ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

    Andrew J. Armstrong;Russell Z. Szmulewitz;Daniel P. Petrylak;Jeffrey Holzbeierlein

  • Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

    George L. Wright;George L. Wright;B. Mayer Grob;B. Mayer Grob;Cara Haley;Cara Haley;Katie Grossman;Katie Grossman

  • Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

    Thomas Powles;Jonathan E Rosenberg;Guru P Sonpavde;Yohann Loriot

  • Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.

    Jonathan E. Rosenberg;Jonathan E. Rosenberg;Peter H. O’Donnell;Arjun V. Balar;Bradley A. McGregor

  • Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu–Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial

    Maha H.A. Hussain;Gary R. MacVicar;Daniel P. Petrylak;Rodney L. Dunn

  • Altered Expression of the Retinoblastoma Gene Product: Prognostic Indicator in Bladder Cancer

    Carlos Cordon-Cardo;David Wartinger;Daniel Petrylak;Guido Dalbagni

  • Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells

    Josep Domingo-Domenech;Samuel J. Vidal;Veronica Rodriguez-Bravo;Mireia Castillo-Martin

  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Thomas Powles;Michiel S van der Heijden;Daniel Castellano;Matthew D Galsky

  • Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

    Susan Halabi;William Kevin Kelly;Hua Ma;Haojin Zhou

  • TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.

    Scott T Tagawa;Arjun V Balar;Daniel P Petrylak;Arash Rezazadeh Kalebasty

  • Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer

    Daniel P. Petrylak;Robert B. Macarthur;John O'Connor;Gary Shelton

  • Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

    Nadeem Sheikh;Daniel Petrylak;Philip Wayne Kantoff;Corazon dela Rosa

  • A pilot study of the vulnerable elders survey‐13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation

    Supriya G. Mohile;Kathryn Bylow;William Dale;James Dignam

Frequent Co-Authors

Maha Hussain
Maha Hussain Northwestern University
Emilia Bagiella
Emilia Bagiella Icahn School of Medicine at Mount Sinai
Walter M. Stadler
Walter M. Stadler University of Chicago
Tomasz M. Beer
Tomasz M. Beer Oregon Health & Science University
E. David Crawford
E. David Crawford University of California, San Diego
Supriya G. Mohile
Supriya G. Mohile University of Rochester Medical Center
Mario A. Eisenberger
Mario A. Eisenberger Johns Hopkins University
Ulka N. Vaishampayan
Ulka N. Vaishampayan University of Michigan–Ann Arbor
David M. Nanus
David M. Nanus Cornell University
Cora N. Sternberg
Cora N. Sternberg Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA offers a range of educational options, many of which are now available online. For those considering alternative routes to traditional medical school, online nursing degrees can provide flexible and affordable pathways.

Becoming a nurse practitioner is a popular choice for those seeking advanced roles. Today, cheapest np programs online allow students to earn their qualification at a reduced cost without relocating or pausing their career. If you're aiming for a foundational nursing career, you may explore the cheapest bsn programs online, offering quality bachelor’s degrees recognized nationwide.

For registered nurses looking to advance their education, numerous what is the cheapest rn to bsn program online opportunities exist, making it easier to upgrade credentials and boost career prospects. Those seeking leadership or research roles might consider doctoral studies; exploring the cheapest dnp programs online can help minimize student debt while expanding professional options.

By carefully selecting accredited, affordable online programs, you can find a pathway that aligns with your career goals and budget.

Best Scientists Citing Daniel P. Petrylak

Trending Scientists

Recently Published Articles